human amelanotic melanoma cells c32  (ATCC)

Journal: Advanced Healthcare Materials

Article Title: Electro‐Stimulated Graphene‐Polymer Nanocomposites Enable Wearable Patches With Feedback‐Controlled Drug Release

doi: 10.1002/adhm.202505894

Figure Lengend Snippet: Schematic of e‐Medi‐Patch setup with plausible (a) mechanism of drug release; (b) Incubation of Medi‐patch (attached to sterilized tape) with cells for in‐vitro experiments (c) Bright field images of C32 cells after 48 h with free NIC and different formulations of medi‐patch exhibiting change in cellular morphology and growth density after 48 h treatment confirming slow and successful release of NIC over time. (d) C32 cells and (e) GR‐PCL incubated C32 cells showed negligible cell death [Hoechst33342 (blue) stains all cells, Calcein AM (green) stains live cells, Propidium iodide (red) stains dead cells] confirming insignificant effect of only GR‐PCL medi‐patch in absence of NIC (f) The % cell viability of C32 population with treatment groups post 48 and 72 h of incubation showed comparable efficiency of NIC, either released from the composites or as a free drug.

Article Snippet: Human melanoma cell line C32 was obtained from American Type Culture Collection (ATCC).

Techniques: Incubation, In Vitro

Journal: Advanced Healthcare Materials

Article Title: Electro‐Stimulated Graphene‐Polymer Nanocomposites Enable Wearable Patches With Feedback‐Controlled Drug Release

doi: 10.1002/adhm.202505894

Figure Lengend Snippet: Comparative Flow Cytometry analysis of cells incubated with Medi‐patch (CD44‐PE have been used as markers) for studying (a) control non‐cancerous b.End3 cells with negligible CD44(+) cell population; (b) C32 control population (c) GR‐PCL increases CD44 expression in C32 (d) loss of stemness property (CD44) in a significant C32 population (∼11%) treated with NIC‐GR‐PCL where effect of release NIC from e‐Medi‐Patch is confirmatory (e) Mechanistic roles of NIC in inhibiting the stem cell phenotype, survival, proliferation, migration in cancer cells (f) In MFI (mean fluorescent intensities) measurements b.End3 cells showed negligible CD44 expression without treatment which increases with GR‐PCL and decreases with NIC‐GR‐PCL medi‐patch (g) C32 showed gradual decrease in CD44 expression with NIC‐medi‐patch confirming efficacy of NIC‐GR‐PCL medi‐patch.

Article Snippet: Human melanoma cell line C32 was obtained from American Type Culture Collection (ATCC).

Techniques: Flow Cytometry, Incubation, Control, Expressing, Migration

Journal: Advanced Healthcare Materials

Article Title: Electro‐Stimulated Graphene‐Polymer Nanocomposites Enable Wearable Patches With Feedback‐Controlled Drug Release

doi: 10.1002/adhm.202505894

Figure Lengend Snippet: In vivo use of e‐Medi‐Patch to evaluate the efficiency in xenograft melanoma nude mouse model. (a) Timeline of experimental procedure with schematic of ‐mouse model. (b) Variation in tumor volume from the group of animals without and with treatment of e‐Medi‐Patch. A representative animal (c) during and (d) after, application of e‐Medi Patch treatment. Change in the impedance values (ΔZ) of the e‐Medi‐Patch after 3 min of treatment on the (e) left side tumor (f) right side tumor. Control indicates animals (N = 2) not treated with e‐Medi‐Patch. Treated (no drug) indicate animals (N = 2) treated with e‐Patch without drug (niclosamide). Treated (drug) indicates animals (N = 3) treated with e‐Medi‐Patch with drug (niclosamide)‐. p value of < 0.05 has been represented as * and > 0.05 as ns. (g) Representative H&E‐stained sections of tissues collected from control animals and (h) e‐Medi‐Patch treated groups. Tissues were collected from C32 cell xenograft tumor, kidney, heart, spleen, liver and lungs. Arrow heads represent loss of tissue integrity in e‐Medi‐Patch treated niclosamide. (Scale: 2 µm).

Article Snippet: Human melanoma cell line C32 was obtained from American Type Culture Collection (ATCC).

Techniques: In Vivo, Control, Staining